Biochemical markers of platelet storage

Abstract

Compositions and methods for determining post-transfusion survival of platelets and the suitability of platelet units for transfusion by measuring the levels of one or more markers in a platelet sample are provided.

1 . A method comprising:
 obtaining a stored platelet (PLT) sample from a stored PLT unit, wherein the stored PLT sample comprises at least one biomarker selected from the group consisting of adenine, 13-HODE/9-HODE, caprylate, laurate, C-glycosyltryptophan, and andro steroid monosulfate 2;   contacting the stored PLT sample with a reagent to form a complex between the reagent and the at least one biomarker;   detecting the complex to obtain data associated with the stored PLT sample, wherein the data comprises expression or activity level data for the at least one biomarker; and   storing the data in a storage memory.   
     
     
         2 . The method of  claim 1 , wherein the data is positively correlated with PLT storage quality of the stored PLT sample when there is a statistically significant increase in the levels of one or more of adenine, C-glycosyltryptophan, and andro steroid monosulfate 2 in the stored PLT sample, and/or when there is a statistically significant decrease in the levels of one or more of 13-HODE/9-HODE, caprylate, and laurate in the stored PLT sample, relative to the corresponding level in a control PLT sample suitable for transfusion. 
     
     
         3 . The method of  claim 1 , wherein the data is negatively correlated with PLT storage quality of the stored PLT sample when there is a statistically significant decrease in the levels of one or more of adenine, C-glycosyltryptophan, and andro steroid monosulfate 2 in the stored PLT sample, and/or when there is a statistically significant increase in the levels of the one or more of 13-HODE/9-HODE, caprylate, and laurate in the stored PLT sample, relative to the corresponding level in a control PLT sample suitable for transfusion. 
     
     
         4 . The method of  claim 1 , wherein the data is obtained at a time the stored PLT sample is obtained. 
     
     
         5 . The method of  claim 1 , wherein the data is obtained during a time that the stored PLT sample has been stored. 
     
     
         6 . The method of  claim 1 , wherein the data is obtained by a method selected from mass spectrometry, enzymatic assay, and enzyme-linked immunosorbent assay (ELISA). 
     
     
         7 . The method of  claim 1 , wherein the data is obtained by a mass spectrometry technique selected from the group consisting of gas-chromatography/mass spectrometry (GC/MS), and liquid chromatography-tandem mass spectrometry (LC/MS/MS). 
     
     
         8 . The method of  claim 1 , wherein the levels of the one or more biomarkers selected from the group consisting of adenine, C-glycosyltryptophan, and andro steroid monosulfate 2 in the stored PLT sample are 2-200 fold higher than the corresponding levels of the same biomarkers in the control PLT sample. 
     
     
         9 . The method of  claim 1 , further comprising administering the stored PLT unit to a subject if the data is positively correlated with PLT storage quality of the stored PLT sample. 
     
     
         10 . The method of  claim 1 , further comprising not administering the stored PLT unit to a subject if the data is negatively correlated with PLT storage quality of the stored PLT sample.